C4 Therapeutics, Inc. Deferred Tax Liabilities, Unrealized Gains on Trading Securities
C4 Therapeutics, Inc. (CCCC) had Deferred Tax Liabilities, Unrealized Gains on Trading Securities of $3.00 thousand as of 2020-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities · last filed 2022-02-24
- 2020-12-31: Deferred Tax Liabilities, Unrealized Gains on Trading Securities $3.00K.
| Period end | Deferred Tax Liabilities, Unrealized Gains on Trading Securities |
|---|---|
| 2020-12-31 | $3.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |